Acknowledgement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2017M3A9G6068245).
References
- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273. https://doi.org/10.1038/s41586-020-2012-7
- Track the Coronavirus Outbreak on Johns Hopkins Live Dashboard | MedPage Today Available online: https://www.medpagetoday.com/infectiousdisease/publichealth/84698 (Accessed on Oct. 10, 2021).
- Hu B, Guo H, Zhou P, Shi Z-L. 2021. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19: 141-154. https://doi.org/10.1038/s41579-020-00459-7
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
- V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. 2021. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19: 155-170. https://doi.org/10.1038/s41579-020-00468-6
- Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, et al. 2021. The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev. 23: 40-47.
- Sahu AK, Mathew R, Bhat R, Malhotra C, Nayer J, Aggarwal P, et al. 2021. Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. QJM 114: 455-463. https://doi.org/10.1093/qjmed/hcab212
- Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3: 673-683. https://doi.org/10.1038/nrd1468
- Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9: eaal3653. https://doi.org/10.1126/scitranslmed.aal3653
- Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al.2020. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382: 2411-2418. https://doi.org/10.1056/nejmoa2012410
- Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. 2020. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. JAMA Netw. Open 3: e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382: 1787-1799. https://doi.org/10.1056/NEJMoa2001282
- James H McMahon, Andrew Udy, Anton Y Peleg. 2020. Remdesivir for the treatment of Covid-19- preliminary report. N. Engl. J. Med. 383: 992-993. https://doi.org/10.1056/nejmc2022236
- WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, et al. 2021. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N. Engl. J. Med. 384: 497-511. https://doi.org/10.1056/NEJMoa2023184
- Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 Available online: https://www.gilead.com/news-and-press/press-room/press-releases/2021/9/veklury-remdesivir-significantly-reduced-risk-ofhospitalization-in-highrisk-patients-with-covid19 (Accessed on Oct. 9, 2021).
- Group TRC. 2021. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384: 693-704. https://doi.org/10.1056/NEJMoa2021436
- RECOVERY Collaborative Group. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England) 397: 1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-0
- Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. 2021. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 9: 1407-1418. https://doi.org/10.1016/S2213-2600(21)00331-3
- Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64: e00819-20.
- Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, Drosten C, Pohlmann S. 2020. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob. Agents Chemother. 64: e00754-20.
- Yamamoto M, Kiso M., Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, et al. 2020. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12: 629. https://doi.org/10.3390/v12060629
- Ko M, Jeon S, Ryu W, Kim S. 2021. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J. Med. Virol. 93: 1403-1408. https://doi.org/10.1002/jmv.26397
- Kumar S, Chandele A, Sharma A. 2021. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 17: e1009885. https://doi.org/10.1371/journal.ppat.1009885
- Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. 20201. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384: 229-237.
- Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. 2021. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 325: 632. https://doi.org/10.1001/jama.2021.0202
- Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore, R, et al. 2021. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384: 238-251. https://doi.org/10.1056/NEJMoa2035002
- Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci, et al. 2021. Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv 2021.05.27.21257096.
- Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al. 2021. Early convalescent plasma for high-risk outpatients with Covid-19. N. Engl. J. Med. 385: 1951-1960. https://doi.org/10.1056/NEJMoa2103784
- Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study - Merck.com Available online: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravirreduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-ormoderat/ (Accessed on Oct. 10, 2021).
- Reynard O, Nguyen X-N, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov V. 2015. Identification of a new ribonucleoside inihibitor of Ebola virus replication. Viruses 7: 6233-6240. https://doi.org/10.3390/v7122934
- Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, et al. 2018. β-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 92: e01965-17.
- Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, et al. 2019. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11: eaax5866. https://doi.org/10.1126/scitranslmed.aax5866
- Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. 2019. Small-molecule antiviral β-D- N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 93: e01348-19.
- Covid-19 Antiviral Efforts | Pfizer Available online: https://www.pfizer.com/science/coronavirus/antiviral-efforts (Accessed on Oct. 10, 2021).
- De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 Years. Clin. Microbiol. Rev. 29: 695-747. https://doi.org/10.1128/CMR.00102-15
- Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21: 1508-1513. https://doi.org/10.1038/nm.3985